Coronary Embolism After Transcatheter Aortic Valve Replacement-Case Series and Review of Literature.
TAVR
aortic stenosis
coronary embolism
myocardial infarction
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 10 2023
15 10 2023
Historique:
received:
22
06
2023
revised:
12
07
2023
accepted:
19
07
2023
medline:
22
9
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Periprocedural systemic embolism is a well-documented complication of transcatheter aortic valve replacement (TAVR). Although the most focus was given to cerebral embolism (which remains unpredictable, difficult to prevent, and a source of increased morbidity and mortality after TAVR), coronary embolism remains less investigated and potentially overlooked. This study provides a case series of 3 patients diagnosed with coronary embolism after TAVR in our institution over a 2-year period (3 of 297 cases, 1%) and a systematic literature review (4 studies; 19 case reports). Overall, coronary embolism associated with TAVR is frequently characterized by proximal vessel occlusion causing ST-elevation myocardial infarction and hemodynamic instability with lower mortality in the acute phase as compared with late coronary embolism. However, it often presents with distal vessel occlusion and minor symptoms that may be overlooked in the periprocedural period. In conclusion, we suggest that TAVR-associated coronary embolism has a much higher prevalence than previously documented. Further studies are warranted to properly assess the prevalence and impact of this phenomenon.
Identifiants
pubmed: 37611416
pii: S0002-9149(23)00694-X
doi: 10.1016/j.amjcard.2023.07.137
pii:
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
234-240Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. Danenberg serves as a clinical proctor for Medtronic and Edwards Lifesciences. The remaining authors have no competing interests to declare.